Andrew R. Burgoyne

•Product Lead/Principal Investigator: - Tri-Lab accelerator-produced Ac-225 (cGMP) from proton irradiated Th-232 - Fabrication of Ra-224/Pb-212 generators from Th-228 - W-188/Re-188 processing - Ba-133 processing •Subject Matter Expert: - Ni-63 characterization and dispensing - Sr-89 processing - Ra-226/Ac-227/Th-228 separations - EMIS ultra high purity U-233/Th-229 separation and dispensing Support radioisotope production of 4501 Operations Group, Isotope Production and Manufacturing Division.

•Product Lead for radioisotopes within Bethel Valley: -Tri-Lab accelerator-produced Ac-225 from proton irradiated Th-232 -W-188/Re-188 Processing -Fabrication of Ra-224/Pb-212 generators from Th-228 -Dispensing of Th-228 from neutron irradiated Ra-226

•Subject-Matter Expert of accelerator produced Ac-225 from Th-232 (Tr-Lab Effort with Los Alamos and Brookhaven National Laboratories). •Product Lead for W-188/Re-188. •Supporting the operators and technical staff of the Bethel Valley Radiochemical Processing Group within the Radioisotope Science and Technology Division. • Building 3047 functions include: radiochemist part of the team performing Ac-227 isolation from Ra-226 and Th-228. • Building 4501 functions include: loading targets from the High Flux Isotope Reactor (HFIR) or the Isotope Production Facility (100 MeV IPF) at Los Alamos National Laboratory or the Brookhaven Linac Isotope Producer (200 MeV BLIP) at Brookhaven National Laboratory into hot cells, performing hot cell/glove box operations towards radioisotope production of Ni-63, Sr-89, Sn-117m, Ba-133, Nd-147/Pm-147, W-188/Re-188, Tri-Lab accelerator produced Ac-225, Th-228 (Ra-224/Pb-212 generators), performing analysis on products and waste, evacuation of waste, dispensing radioisotopes, generating radioisotope spec sheets for customers of the National Isotope Development Center and revising work control through procedures.

•SCK CEN Highlights 2020: From pain relief to cancer treatment - SCK CEN conducts research on samarium-153 as a theranostic radioisotope •SCK CEN Highlights 2019: Terbium-161: an emerging radioisotope in the fight against cancer - SCK CEN has taken the next step in the production chain for the first time •Radioisotope Production - Lead scientist responsible for nca Tb-161, nca Lu-177 (primary developer for the purification technology licensed to POINT Biopharma), W-188/Re-188 used for targeted radionuclide therapy radiopharmaceutical development. Established collaboration with MEDICIS/CERN for the production of mass separated radioisotopes (Tb-155 and high specific activity Sm-153) for targeted radionuclide therapy. •Radiopharmaceutical Development - Scientist performing in-house pre-clinical evaluation of radiopharmaceuticals produced. •Molecular Synthesis - Responsible for in-house new bifunctional chelator design towards new radiopharmaceuticals. Lead in coordination chemistry in radiopharmaceutical development. •NURA Contract Manufacturing Organization - Responsible for up-scaling and bulk radioisotope purification process. •NURA Contract Research Organization Committee - Secondary representative for Radiochemistry Group. •NURA Scientific Committee - Radiochemistry and Radiopharmacy representative. •MSc and PhD Supervisor - Responsible for several candidates working on the development and evaluation of radiopharmaceuticals. •Collaborations: MEDICIS-CERN/Arronax (Tb-155 Production), MEDICIS-CERN/KULeuven (High Specific Activity Sm-153 Production), KULeuven/Ablynx (Tb-161 Radiopharmaceutical), KULeuven (Tb-161 NPs, Synthesis of Chelator for Sm-153/Tb-161/Lu-177 and Novel Chelator Design for Ac-225), Chimie ParisTech PSL (Re-188 Radiopharmaceutical), Técnico Lisboa (Tb-161/Lu-177/In-111 Auger Electron Comparison), TRIUMF (Tb-161 Radiopharmaceutical), UGent/Ablynx (Re-188 Radiopharmaceutical), ULiège (Irradiated Pharmaceuticals in Space)

•Drug design, synthesis, characterization and biological evaluation involving tritiated (H-3) radioligand binding assays of nicotinic acetylcholine receptors as potential agents against neurodegenerative diseases. •Performed typical organic synthetic chemistry, Q-Tube and microwave chemistry along with Pd-based Buchwald-Hartwig cross coupling reactions to prepare a large series of new potential central nervous system disorder drugs. •Responsible for management of radiological and molecular synthesis labs.

•Research performed at the Malaviya National Institute of Technology (MNIT) in Jaipur, India on joint bilateral collaboration between South Africa and India entitled "New Perspectives to Advance Green Medicinal Chemistry". Performed Cu(I) catalyzed reactions on click type chemistry reactions between alkynes and azides to yield biologically active agents in Jaipur, India (2015)

•Selected as Top 20 South African Graduates by GlaxoSmithKline and spent a week receiving training on lab techniques and pharmaceutical drug discovery

Synthesis, characterization and biological evaluation of new polynuclear dendritic type scaffolds for coordination with platinum group metal precursors as anticancer agents

Synthesis, post-synthetic modification, characterization and catalytic evaluation of metal organic frameworks (MOFs) in the Knoevenagel Condensation and Heck cross-coupling reactions

Organic synthesis step-wise project involving D-glucose sugars. Inorganic synthetic projects involving preparation and modifications to ferrocene for use as catalysts and also the preparation of several Rhodium(I) bis-phosphine complexes along with UV-Vis kinetic studies of the lability of P-type ligands. Crystallographic project involving crystal growing and the use of a single crystal X-ray diffractometer (XRD)